CIS Oncology sees promising opportunities in South Africa
By Sarah Greer:
Invest Northern Ireland are assisting CIS Oncology in Belfast to pinpoint opportunities in South Africa for its sophisticated software for cancer treatment.Following the Invest NI ‘Going South Africa’ initiative, the company – part of the CIS Healthcare operation – is returning to the market this month. The initiative is designed to encourage and assist local companies to grasp the growing business opportunities in South Africa.
During this follow-up visit, the company has a series of meetings with potential clients interested in the unique ChemoCare software – an electronic prescribing system and management technology for cancer patients.
Belfast-based CIS Oncology was one of the first local companies to sign up to the Going South Africa initiative. Dr Vicky Kell, Invest NI Trade Director, announced the assistance to support the company during a visit to their offices in the Titanic Quarter.
Dr Kell said: “CIS Oncology identified the potential in South Africa for its products from the nation’s extensive expenditure on healthcare and has worked with us to develop increased detailed market knowledge and to pinpoint potential clients. Our advisors there have also helped the company with up-to-date market trends, performance information and knowledge, and are continuing to work with the company to deliver market success.
“Currently, South Africa is spending 8.5 per cent of GDP on health, well ahead of other parts of Africa. It has developed sophisticated health facilities particularly in urban centres such as Johannesburg, Cape Town and Durban but has still much to do across a huge nation. South Africa is well aligned to Northern Ireland businesses as this is a nation in which English is the language of business and with financial and legal systems shaped by its historic relationship with Britain and Ireland. Also there is never more than a two hour time difference from Northern Ireland.”
Business Development Consultant Kerry Brown outlined the company’s plans, saying: “We had been aware of possible opportunities in South Africa before the Invest NI concept was introduced. When it was launched, I jumped at the opportunity that it offered to take advice and the practical support that Invest NI’s advisors provide.
“ChemoCare is designed for specialist cancer hospitals and clinics and is highly complex. It requires significant commitment from our customers to purchase and implement, therefore securing business always involves lengthy negotiations which means spending considerable time in the market.”
ChemoCare is designed for specialist cancer hospitals and clinics. With over 15 years experience, CIS Oncology is the leading supplier of chemotherapy prescribing and management systems in the UK, holding approximately 70% of the UK market.
They support adult and paediatric, solid and haematological oncology prescribing and management. It is the only true paediatric solution have been developed with the support of the Children’s Cancer Leukaemia Group.